{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"INVA","limit":50},"count":50,"signals":[{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":15,"context":"tock equal to $125,000 divided by the closing price of a share of our Common Stock on the date of grant, rounded down to the nearest whole share. This initial RSU award vests in two equal annual installments over the directors first two years of service. In addition, the new non-employee director also receives the annual equity award described above (if joining on the date of our annual meeting of st","filed_date":"2026-03-24","accession":"0001140361-26-010912","full_text":"https://origin.rootz.global/static/filing/0001140361-26-010912.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":66,"context":"rs of more than 5% of our capital stock, or entities affiliated with them, had or will have a direct or indirect material interest. Strategic Partnership with Sarissa Capital On December 11, 2020, we entered into a strategic partnership with Sarissa Capital designed to accelerate the execution of our strategy and enhance returns on capital. The partnership comprises (i) a strategic advisory agreement, pursuant to which and subject t","filed_date":"2026-03-24","accession":"0001140361-26-010912","full_text":"https://origin.rootz.global/static/filing/0001140361-26-010912.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":63,"context":"U.S. requirements at any time during the product development process, approval process or after approval may subject us to a variety of administrative or judicial sanctions, any of which could have a material adverse effect on us. These sanctions could include: refusal to approve pending applications; withdrawal of an approval; imposition of a clinical hold; warning letters, untitled letters and similar communications;","filed_date":"2026-02-25","accession":"0001193125-26-071776","full_text":"https://origin.rootz.global/static/filing/0001193125-26-071776.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":17,"context":"nvestments and marketable securities, primarily corporate notes, government securities, government agencies, and commercial papers. On December 11, 2020, we entered into the Partnership Agreement and invested $300 million of our cash reserves to be managed by Sarissa Capital as the investment manager to the Partnership.  The risks associated with this investment strategy may be substantially greater than the risks ass","filed_date":"2026-02-25","accession":"0001193125-26-071776","full_text":"https://origin.rootz.global/static/filing/0001193125-26-071776.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":71,"context":"s of more than 5% of our capital stock, or entities affiliated with them, had or will have a direct or indirect material interest.  Strategic Partnership with Sarissa Capital  On December11, 2020, we entered into a strategic partnership with Sarissa Capital designed to accelerate the execution of our strategy and enhance returns on capital. The partnership comprises (i)a strategic advisory agreement, pursuant to which and subject to","filed_date":"2025-04-08","accession":"0001193125-25-075695","full_text":"https://origin.rootz.global/static/filing/0001193125-25-075695.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":62,"context":"U.S. requirements at any time during the product development process, approval process or after approval may subject us to a variety of administrative or judicial sanctions, any of which could have a material adverse effect on us. These sanctions could include: refusal to approve pending applications; withdrawal of an approval; imposition of a clinical hold; warning letters, untitled letters and similar communications;","filed_date":"2025-02-26","accession":"0000950170-25-027864","full_text":"https://origin.rootz.global/static/filing/0000950170-25-027864.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":12,"context":"nvestments and marketable securities, primarily corporate notes, government securities, government agencies, and commercial papers. On December 11, 2020, we entered into the Partnership Agreement and invested $300 million of our cash reserves to be managed by Sarissa Capital as the investment manager to the Partnership.  While we expect that a portion of our revenues will continue to be derived from our royalty manage","filed_date":"2025-02-26","accession":"0000950170-25-027864","full_text":"https://origin.rootz.global/static/filing/0000950170-25-027864.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":21,"context":"tock equal to $125,000 divided by the closing price of a share of our Common Stock on the date of grant, rounded down to the nearest whole share. This initial RSU award vests in two equal annual installments over the directors first two years of service. In addition, the new non-employee director also receives the annual equity award described above (if joining on the date of our annual meeting of st","filed_date":"2024-04-29","accession":"0001193125-24-122923","full_text":"https://origin.rootz.global/static/filing/0001193125-24-122923.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":36,"context":"s of more than 5% of our capital stock, or entities affiliated with them, had or will have a direct or indirect material interest.  Strategic Partnership with Sarissa Capital  On December11, 2020, we entered into a strategic partnership with Sarissa Capital designed to accelerate the execution of our strategy and enhance returns on capital. The partnership comprises (i)a strategic advisory agreement, pursuant to which and subject to","filed_date":"2024-04-29","accession":"0001193125-24-122923","full_text":"https://origin.rootz.global/static/filing/0001193125-24-122923.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":54,"context":"U.S. requirements at any time during the product development process, approval process or after approval may subject us to a variety of administrative or judicial sanctions, any of which could have a material adverse effect on us. These sanctions could include: refusal to approve pending applications; withdrawal of an approval; imposition of a clinical hold; warning letters, untitled letters and similar communications;","filed_date":"2024-02-29","accession":"0000950170-24-023237","full_text":"https://origin.rootz.global/static/filing/0000950170-24-023237.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":24,"context":"tock equal to $125,000 divided by the closing price of a share of our Common Stock on the date of grant, rounded down to the nearest whole share. This initial RSU award vests in two equal annual installments over the directors first two years of service. In addition, the new non-employee director also receives the annual equity award described above (if joining on the date of our annual meeting of st","filed_date":"2023-04-28","accession":"0001193125-23-127442","full_text":"https://origin.rootz.global/static/filing/0001193125-23-127442.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":36,"context":"sold to Royalty Pharma Plc in July 2022. In connection with that sale, the Company received approximately $282million in proceeds.  Strategic Partnership with Sarissa Capital  On December11, 2020, we entered into a strategic partnership with Sarissa Capital designed to accelerate the execution of our strategy and enhance returns on capital. The partnership comprises (i)a strategic advisory agreement, pursuant to which and subject to","filed_date":"2023-04-28","accession":"0001193125-23-127442","full_text":"https://origin.rootz.global/static/filing/0001193125-23-127442.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":16,"context":"U.S. requirements at any time during the product development process, approval process or after approval may subject us to a variety of administrative or judicial sanctions, any of which could have a material adverse effect on us. These sanctions could include: &#x2022; refusal to approve pending applications; &#x2022; withdrawal of an approval; &#x2022; imposition of a clinical hold; &#x2022; warning letters, untitled","filed_date":"2023-02-28","accession":"0000950170-23-005168","full_text":"https://origin.rootz.global/static/filing/0000950170-23-005168.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":21,"context":"tock equal to $125,000 divided by the closing price of a share of our Common Stock on the date of grant, rounded down to the nearest whole share. This initial RSU award vests in two equal annual installments over the directors first twoyears of service. In addition, the new non-employee director also receives the annual equity award described above (if joining on the date of our annual meeting of sto","filed_date":"2022-03-25","accession":"0001104659-22-038101","full_text":"https://origin.rootz.global/static/filing/0001104659-22-038101.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":30,"context":"of the common stock then owned by GSK for total consideration of approximately $394million (including related transaction costs).  Strategic Partnership with Sarissa Capital  On December11, 2020, we entered into a strategic partnership with Sarissa Capital designed to accelerate the execution of our strategy and enhance returns on capital. The partnership comprises (i)a strategic advisory agreement, pursuant to which and subject to","filed_date":"2022-03-25","accession":"0001104659-22-038101","full_text":"https://origin.rootz.global/static/filing/0001104659-22-038101.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":9,"context":"wers, including the ability to suspend or delay issuance of approvals, seize products, withdraw approvals, enjoin violations, and institute criminal prosecution, any one or more of which could have a material adverse effect upon our business, financial condition and results of operations. Outside the United States, the ability to market products will also depend on receiving marketing authorizations from the appropriate","filed_date":"2022-02-28","accession":"0000950170-22-002169","full_text":"https://origin.rootz.global/static/filing/0000950170-22-002169.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":19,"context":"tock equal to $125,000 divided by the closing price of a share of our Common Stock on the date of grant, rounded down to the nearest whole share. This initial RSU award vests in two equal annual installments over the directors first twoyears of service. In addition, the new non-employee director also receives the annual equity award described above (if joining on the date of our annual meeting of sto","filed_date":"2021-04-02","accession":"0001104659-21-046174","full_text":"https://origin.rootz.global/static/filing/0001104659-21-046174.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":32,"context":"m collaborative arrangements with a related party on our consolidated statements of income for the year ended December31, 2020.  35 Strategic Partnership with Sarissa Capital  On December11, 2020, we entered into a strategic partnership with Sarissa Capital designed to accelerate the execution of our strategy and enhance returns on capital. The partnership comprises (i)a strategic advisory agreement, pursuant to which and subject to","filed_date":"2021-04-02","accession":"0001104659-21-046174","full_text":"https://origin.rootz.global/static/filing/0001104659-21-046174.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":9,"context":"wers, including the ability to suspend or delay issuance of approvals, seize products, withdraw approvals, enjoin violations, and institute criminal prosecution, any one or more of which could have a material adverse effect upon our business, financial condition and results of operations. Outside the United States, the ability to market products will also depend on receiving marketing authorizations from the appropriate","filed_date":"2021-02-25","accession":"0001104659-21-028328","full_text":"https://origin.rootz.global/static/filing/0001104659-21-028328.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":29,"context":"of director nominees for election to the Board of Directors at the Annual Meeting. At the Annual Meeting, we will ask you to: (1) elect five directors; (2) cast a non-binding advisory vote to approve named executive officer compensation; (3) ratify the selection of Grant Thornton LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2020; and (4) take","filed_date":"2020-03-11","accession":"0001047469-20-001393","full_text":"https://origin.rootz.global/static/filing/0001047469-20-001393.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":9,"context":"wers, including the ability to suspend or delay issuance of approvals, seize products, withdraw approvals, enjoin violations, and institute criminal prosecution, any one or more of which could have a material adverse effect upon our business, financial condition and results of operations. Outside the United States, our collaborative partners ability to market partnered products will also depend on receiving marketing au","filed_date":"2020-02-19","accession":"0001104659-20-022807","full_text":"https://origin.rootz.global/static/filing/0001104659-20-022807.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":41,"context":"of director nominees for election to the Board of Directors at the Annual Meeting. At the Annual Meeting, we will ask you to: (1) elect five directors; (2) cast a non-binding advisory vote to approve named executive officer compensation; (3) ratify the selection of Grant Thornton LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2019; and (4) take","filed_date":"2019-03-13","accession":"0001047469-19-001164","full_text":"https://origin.rootz.global/static/filing/0001047469-19-001164.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":93,"context":"of director nominees for election to the Board of Directors at the Annual Meeting. At the Annual Meeting, we will ask you to: (1) elect five directors; (2) cast a non-binding advisory vote to approve named executive officer compensation; (3) ratify the selection of Ernst & Young LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2018; and (4) take a","filed_date":"2018-03-23","accession":"0001047469-18-002075","full_text":"https://origin.rootz.global/static/filing/0001047469-18-002075.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":14,"context":"t, Chief Commercial Officer |  | |  Theodore J. Witek, Jr., Dr.P.H. |  |  |  59 |  |  Senior Vice President, Chief Scientific Officer |  | (1)Member of the Board of Directors  *Michael W. Aguiar* was appointed President and Chief Executive Officer of Innoviva, Inc. and became a member of our Board of Directors in August 2014. He joined Innoviva as Senior Vice President and Chief Financial Officer in March 2005. Prior to joining Innoviva, Mr. A","filed_date":"2017-02-28","accession":"0001047469-17-001057","full_text":"https://origin.rootz.global/static/filing/0001047469-17-001057.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":75,"context":"Common Stock pursuant to its periodic \"top-up\" rights under our Amended and Restated Governance Agreement, dated as of June 4, 2004, as amended, among us, GSK and certain GSK affiliates, for a total investment of $6.5 million. The  52 Amended and Restated Governance Agreement and the related \"top-up\" rights terminated in September 2015.  |  |  |  |  |  |  |  |  |  | |  |  |  Common Stock Shares Purchased |  |  Aggregate P","filed_date":"2016-03-25","accession":"0001047469-16-011574","full_text":"https://origin.rootz.global/static/filing/0001047469-16-011574.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":17,"context":"re J. Witek, Jr., Dr.P.H. |  |  |  58 |  |  Senior Vice President, Chief Scientific Officer |  | (1)Member of the Board of Directors  9 [Table of Contents](#bg77801a_main_toc) *Michael W. Aguiar* was appointed President and Chief Executive Officer of Innoviva, Inc. and became a member of our Board of Directors in August 2014. He joined Innoviva as Senior Vice President and Chief Financial Officer in March 2005. Prior to joining Innoviva, Mr. A","filed_date":"2016-02-24","accession":"0001047469-16-010381","full_text":"https://origin.rootz.global/static/filing/0001047469-16-010381.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":100,"match_count":17,"context":"tock equal to $250,000 divided by the closing price of a share of our common stock on the date of grant, rounded down to the nearest whole share. This initial RSU award vests in two equal annual installments over the director's first two years of service. In addition, the new non-employee director also receives the annual equity award described above (if joining on the date of our annual meeting of s","filed_date":"2015-03-24","accession":"0001047469-15-002647","full_text":"https://origin.rootz.global/static/filing/0001047469-15-002647.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":71,"context":"common stock pursuant to its periodic \"top-up\" rights under our Amended and Restated Governance Agreement, dated as of June 4, 2004, as amended, among us, GSK and certain GSK affiliates, for a total investment of $38.1 million.  |  |  |  |  |  |  |  |  |  | |  |  |  Common Stock Shares Purchased |  |  Aggregate Purchase Price (in thousands) |  |  | |  Purchase dates |  |  |  |  |  |  |  |  | |  February 11, 2014 |  |  |  3","filed_date":"2015-03-24","accession":"0001047469-15-002647","full_text":"https://origin.rootz.global/static/filing/0001047469-15-002647.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":26,"context":"ntly hired executive officers into our management team, and on those individuals' ability to develop and maintain an effective working relationship. Our failure to integrate recently and subsequently appointed directors and executive officers, including our new chief executive officer and chief financial officer, with other members of management could result in inefficiencies in the conduct of our business, which can adversely affect our","filed_date":"2015-02-27","accession":"0001047469-15-001415","full_text":"https://origin.rootz.global/static/filing/0001047469-15-001415.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":24,"context":"15, 2014 and as chairman of our Board and as a director effective as of October 30, 2014. We have appointed Michael W. Aguiar as our chief executive officer and as a member of our Board and recently appointed Eric dEsparbes as our chief financial officer. We expect to continue to expand our management team in the future. Our future performance will depend significantly on our ability to successfully integrate our new directors into","filed_date":"2014-11-04","accession":"0001104659-14-076493","full_text":"https://origin.rootz.global/static/filing/0001104659-14-076493.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":29,"context":"-cash related items of: $28.9 million consisting of stock- based compensation expense of $21.3 million, depreciation and amortization expense of $6.2 million and amortization on premium of short-term investment of $1.4 million; $8.2 million increase in interest payments on convertible subordinated notes payable; $1.9 million used to increase inventories; $1.9 million used to decrease accrued personnel-related expenses and","filed_date":"2014-08-07","accession":"0001104659-14-058343","full_text":"https://origin.rootz.global/static/filing/0001104659-14-058343.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":94,"context":"common stock pursuant to its periodic \"top-up\" rights under our Amended and Restated Governance Agreement, dated as of June 4, 2004, as amended, among us, GSK and certain GSK affiliates, for a total investment of $126.0 million.  |  |  |  |  |  |  |  |  |  | |  |  |  Common Stock Shares Purchased |  |  Aggregate Purchase Price (in thousands) |  |  | |  Purchase dates |  |  |  |  |  |  |  |  | |  February 15, 2013 |  |  |  1","filed_date":"2014-04-15","accession":"0001047469-14-003812","full_text":"https://origin.rootz.global/static/filing/0001047469-14-003812.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":13,"context":"common stock pursuant to its periodic \"top-up\" rights under our Amended and Restated Governance Agreement, dated as of June 4, 2004, as amended, among us, GSK and certain GSK affiliates, for a total investment of $126.0 million. As of February 14, 2014, GSK beneficially owned approximately 27.0% of our outstanding capital stock.  **Program Highlights** Respiratory Programs with GSK  *RELVAR/BREO ELLIPTA (fluticasone furoate","filed_date":"2014-03-03","accession":"0001047469-14-001691","full_text":"https://origin.rootz.global/static/filing/0001047469-14-001691.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":100,"match_count":41,"context":"prior to the Closing of the following further conditions: (i) (A) the representations and warranties of Purchaser contained in Sections 5.1 and 5.2 (1) that are qualified by materiality or Purchaser Material Adverse Effect shall be true in all respects at and as of the Closing Date as if made at and as of such date, and (2) that are not qualified by materiality or Purchaser Material Adverse Effect shall be true in all","filed_date":"2013-05-16","accession":"0001104659-13-042431","full_text":"https://origin.rootz.global/static/filing/0001104659-13-042431.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":100,"match_count":84,"context":",953 shares of our common stock. On May 16, 2012, we issued and Glaxo Group Limited, an affiliate of GSK, purchased 10,000,000 shares of our common stock at a price of $21.2887 per share, for a total investment of $212.9 million.  In addition, in 2012 Glaxo Group Limited purchased shares of our common stock pursuant to its periodic \"top-up\" rights under the Governance Agreement for a total investment of $16.8 million as foll","filed_date":"2013-03-12","accession":"0001047469-13-002600","full_text":"https://origin.rootz.global/static/filing/0001047469-13-002600.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":99,"match_count":8,"context":"wers, including the ability to suspend or delay issuance of approvals, seize products, withdraw approvals, enjoin violations, and institute criminal prosecution, any one or more of which could have a material adverse effect upon our business, financial condition and results of operations.  Outside the United States, our collaborative partner's ability to market partnered products will also depend on receiving marketing","filed_date":"2019-02-19","accession":"0001047469-19-000541","full_text":"https://origin.rootz.global/static/filing/0001047469-19-000541.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"tock equal to $125,000 divided by the closing price of a share of our Common Stock on the date of grant, rounded down to the nearest whole share. This initial RSU award vests in two equal annual installments over the directors first two years of service. In addition, the new non-employee director also receives the annual equity award described above (if joining on the date of our annual meeting of st","filed_date":"2025-04-08","accession":"0001193125-25-075695","full_text":"https://origin.rootz.global/static/filing/0001193125-25-075695.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"the ATTACK Phase 3 registration clinical trial, provides a potentially accelerated path for regulatory approval and commercialization in China and Asia-Pacific territories. Zai Lab supported the enrollment of approximately 25% of the evaluable patients in ATTACK from China, which we believe will support a regulatory submission in China. Under our agreement with Zai Lab, we receive upfront, milestone","filed_date":"2023-02-28","accession":"0000950170-23-005168","full_text":"https://origin.rootz.global/static/filing/0000950170-23-005168.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"tock equal to $125,000 divided by the closing price of a share of our Common Stock on the date of grant, rounded down to the nearest whole share. This initial RSU award vests in two equal annual installments over the director's first two years of service. In addition, the new non-employee director also receives the annual equity award described above (if joining on the date of our annual meeting of s","filed_date":"2019-03-13","accession":"0001047469-19-001164","full_text":"https://origin.rootz.global/static/filing/0001047469-19-001164.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"tock equal to $250,000 divided by the closing price of a share of our common stock on the date of grant, rounded down to the nearest whole share. This initial RSU award vests in two equal annual installments over the director's first two years of service. In addition, the new non-employee director also receives the annual equity award described above (if joining on the date of our annual meeting of s","filed_date":"2016-03-25","accession":"0001047469-16-011574","full_text":"https://origin.rootz.global/static/filing/0001047469-16-011574.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":93,"match_count":11,"context":"of August 15, 2014 and as chairman of our Board and as a director effective as of October 30, 2014. We have appointed Michael W. Aguiar as our chief executive officer and as a member of our Board and appointed Eric dEsparbes as our chief financial officer. We expect to continue to expand our management team in the future. Our future performance will depend significantly on our ability to successfully integrate our new directors into","filed_date":"2015-05-08","accession":"0001104659-15-036218","full_text":"https://origin.rootz.global/static/filing/0001104659-15-036218.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"to complete our clinical trials in a timely manner, if at all, for example because the number of patients required for clinical trials of our product candidates may be larger than we anticipate; enrollment in these clinical trials may be slower than we anticipate, participants may drop out of these clinical trials at a higher rate than we anticipate, or we may fail to recruit suitable patients to pa","filed_date":"2026-02-25","accession":"0001193125-26-071776","full_text":"https://origin.rootz.global/static/filing/0001193125-26-071776.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":88,"match_count":11,"context":"ock equal to $250,000 divided by the closing price of a share of our Common Stock on the date of grant, rounded down to the nearest whole share. This initial RSU award vested in two equal annual installments over the director's first two years of service. In addition, the new non-employee director also received the annual equity award described above (if joining on the date of our annual meeting of s","filed_date":"2018-03-23","accession":"0001047469-18-002075","full_text":"https://origin.rootz.global/static/filing/0001047469-18-002075.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"risk_factor","strength":82,"match_count":4,"context":"wers, including the ability to suspend or delay issuance of approvals, seize products, withdraw approvals, enjoin violations, and institute criminal prosecution, any one or more of which could have a material adverse effect upon our business, financial condition and results of operations.  Outside the United States, our collaborative partner's ability to market partnered products will also depend on receiving marketing","filed_date":"2018-02-23","accession":"0001047469-18-001016","full_text":"https://origin.rootz.global/static/filing/0001047469-18-001016.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"to complete our clinical trials in a timely manner, if at all, for example because the number of patients required for clinical trials of our product candidates may be larger than we anticipate; enrollment in these clinical trials may be slower than we anticipate, participants may drop out of these clinical trials at a higher rate than we anticipate, or we may fail to recruit suitable patients to pa","filed_date":"2025-02-26","accession":"0000950170-25-027864","full_text":"https://origin.rootz.global/static/filing/0000950170-25-027864.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"tock equal to $125,000 divided by the closing price of a share of our Common Stock on the date of grant, rounded down to the nearest whole share. This initial RSU award vests in two equal annual installments over the director's first two years of service. In addition, the new non-employee director also receives the annual equity award described above (if joining on the date of our annual meeting of s","filed_date":"2020-03-11","accession":"0001047469-20-001393","full_text":"https://origin.rootz.global/static/filing/0001047469-20-001393.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":80,"match_count":10,"context":"0: | | | | | | | | Name | | Age | | Positions Held | | | Geoffrey Hulme | | 53 | | Interim Principal Executive Officer | | | Marianne Zhen | | 51 | | Chief Accounting Officer | | *Geoffrey Hulme* was appointed Interim Principal Executive Officer in May 2018. Prior to his hiring, Mr.Hulme served as the owner and manager of Steel Valley CapitalLLC since 2016 and Steel Valley AdvisorsLLC, a registered investment adviser, since 2017. Previously,","filed_date":"2020-02-19","accession":"0001104659-20-022807","full_text":"https://origin.rootz.global/static/filing/0001104659-20-022807.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":80,"match_count":10,"context":"Name |  |  Age |  |  Positions Held |  | |  Geoffrey Hulme |  |  52 |  |  Interim Principal Executive Officer |  | |  Marianne Zhen |  |  50 |  |  Chief Accounting Officer |  | *Geoffrey Hulme* was appointed Interim Principal Executive Officer in May 2018. Prior to his hiring, Mr. Hulme served as the owner and manager of Steel Valley Capital LLC since 2016 and Steel Valley Advisors LLC, a registered investment adviser, since 2017. Previous","filed_date":"2019-02-19","accession":"0001047469-19-000541","full_text":"https://origin.rootz.global/static/filing/0001047469-19-000541.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":77,"match_count":9,"context":"4 and as Chairman of our Board and as a director effective as of October 30, 2014. Since the Spin-Off, we have appointed Michael W. Aguiar as our Chief Executive Officer and as a member of our Board, appointed Eric dEsparbes as our Chief Financial Officer and appointed Michael E. Faerm as our Chief Business Officer. We expect to continue to expand our management team in the future. Our future performance will depend significantly on","filed_date":"2015-08-06","accession":"0001104659-15-057090","full_text":"https://origin.rootz.global/static/filing/0001104659-15-057090.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"INVA","company":"Innoviva, Inc.","exchange":"Nasdaq","sector":"Pharmaceutical Preparations","signal_type":"strategic_event","strength":74,"match_count":8,"context":"nvestments and marketable securities, primarily corporate notes, government securities, government agencies, and commercial papers. On December 11, 2020, we entered into the Partnership Agreement and invested $300 million of our cash reserves to be managed by Sarissa Capital as the investment manager to the Partnership.  While we expect that a portion of our revenues will continue to be derived from our royalty manage","filed_date":"2024-02-29","accession":"0000950170-24-023237","full_text":"https://origin.rootz.global/static/filing/0000950170-24-023237.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"492513db40e69132c0d5b1e5a29168e3058a0f6d1edf8e17de98b07e26c74690","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"59d7494726c55395f928d0bb7dcaa0d27e236312dbfa11bc9b4c167426972490","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":44,"hourly_limit":500,"remaining":456,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}